LEIDEN, The Netherlands and BERLIN, Germany, 05 July 2022 / B3C newswire / — ProteoNic BV, a leading provider of premium vector technologies and services for the efficient production of biological products, and FyoniBio GmbH, a biopharmaceutical contract development organization, today announced that they have entered into a technology licensing agreement.
Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights to implement the ProteoNic technology into its proprietary CHOnamite® platform. As a result, FyoniBio’s customers will benefit from expanded cell line development capabilities and significantly reduced commodity costs for their products.
The financial terms of the agreement include milestone payments to ProteoNic on a product basis.
ProteoNic 2G UNic™ premium protein expression technology improves production levels across a range of mammalian cell types, selection systems and product classes. This is achieved through the combined effect of new genetic elements that together increase the production of the recombinant protein at different levels. The technology increases production levels of difficult-to-produce complex proteins, including bispecific and fusion proteins, as well as product levels already in the multiple g/L range. In addition, 2G UNic™ can be used to enhance the performance of other expression enhancement technologies.
Frank Pieper, CEO of ProteoNic, commented: “We are delighted to be able to contribute to achieving the best results for FyoniBio and its customers. In this agreement, FyoniBio will play an active role in disseminating our world-class technology to product developers.”
Lars Stökl, Managing Director of FyoniBio added: “We believe in providing the most efficient processes and the best solutions to our customers. By offering ProteoNic’s 2G UNic™ technology in combination with our proprietary high performance cell line platforms, our customers have multiple options to achieve the best possible outcome”.
ProteoNic is a privately held company with offices in Leiden, The Netherlands and the Boston area, USA. The company offers technologies and services to generate cell lines with significantly improved production characteristics of biologics, including production rates and stability. The company commercializes its proprietary 2G UNic™ technology through license and partner agreements.
FyoniBio is a contract development and clinical laboratory company with 20 years of experience developing biopharmaceutical products for clients. FyoniBio is ISO9001 certified and operates partly under GCLP. Comprehensive one-stop services, from branch development to RCB for CHO and GEX cell lines, including process development ready for transfer to the GMP facility of customers’ choice, are offered in addition to cutting-edge glycobiology know-how, incl. MS-based glycan and protein analysis, bioassay development and excellent know-how in clinical PK, biomarker analysis and immunogenicity. FyoniBio is part of the Canton Biologics Group, a privately funded scientific enterprise located in the Greater Bay Area of Canton, China.
Mark Posno, Ph.D
Vice President Business Development
+1 617 480 8016
Ulrike Scheffler, Ph.D
Senior Director Business Development
+49 30 94892500
Keywords: technology transfer; Cell Line Development; Cell proliferation; cells cultured; Recombinant proteins; cell line; Cloned cells; Cloning, molecular; Laboratories; Biological products; Biotechnology; technology; trade; Licensing; The Netherlands
Posted by B3C newswire